Neuroprotection simply means protecting neurons by reestablishing blood flow and perfusion after a loss of oxygen to the brain. We see these drugs are currently marketed to those who suffer from stroke.
I wrote about this subtle shift from drugs which modulate the immune system to drugs which address blood flow in 2013. Here's that post:
Ironically, ibudiblast has already been studied in a phase II trial involving 292 patients with relapsing MS and was found to decrease relapses.
When Dr. Zamboni discovered the link to slowed venous return, hypoperfusion and MS, he opened up a new way of looking at the MS disease process. Although neurologists and MS specialists will not say this, he has changed how they are studying the MS disease process and how they are developing drugs to treat MS.
And, not coincidently, one such researcher is Dr. Robert Fox. In 2010, Dr. Fox, a neurologist, received money from the MS Society to study CCSVI, a vascular disorder. A medical student in his lab discovered never before seen venous malformations in the jugular veins of cadavers of people with MS. And in 2011, the results of this study cause quite a stir at ECTRIMS.